

**Table 1:** Characteristics of MDR-TB patients in HCMC from 2011 to 2015

Characteristic	n (%)
Total	2,267
Age at diagnosis (years, median (IQR))	43 (33-53)
≥ 60 years old	197 (8.7%)
18-60 years old	2,038 (89.9%)
≤18 years old	32 (1.4%)
Male	1,716 (75.7%)
Site of disease	
Pulmonary	2,237 (98.7%)
Multi-organ *	37 (1.7%)
Extra pulmonary	67 (3%)
Lymphadenitis	23
Meningitis	21
Pleuritis	8
Bone and vertebral	4
Soft tissue	1
Gastro-intestinal	1
Registration group	
New	128 (5.6%)
Relapse	679 (30%)
Failure of regimen 1	512 (22.6%)
Failure of regiment 2	852 (37.6%)
Treatment after lost to follow-up	47 (2.1%)
Transfer	1 (0%)
Other	46 (2%)
Not recorded	2 (0.1%)

Regimen of previous treatment	
I	914 (40.3%)
II	1012 (44.6%)
III	2 (0.1%)
IV	54 (2.4%)
No history of previous treatment	128 (5.6%)
Unclear history	157 (7%)
BMI at diagnosis (kg/m <sup>2</sup> )	
	n=1816
Median (IQR)	17.88 (15.78-19.98)
Overweight (BMI≥25)	46 (2.5%)
Normal BMI (BMI: 18.5-25)	721 (39.7%)
Mild underweight (BMI: 17-18.5)	343 (18.9%)
Moderate underweight (BMI: 16-17)	250 (13.8%)
Severe underweight (BMI≤16)	456 (25.1%)
HIV positive	
	205/2,137 tested for HIV (9.6%)
Diabetes	
	359/1,189 (30.2%)
Unknown history of diabetes	
	1,078 (47.5%)
Initial Diagnosis Method	
DST	275 (12.1%)
Xpert	1,276 (56.3%)
Hain	705 (31.1%)
DST of last treatment episode	7 (0.3%)
Missing data	4 (0.2%)
AFB smear at baseline	
Positive	1,748 (77.1%)
< 1+	158 (9%)

1+	895 (51.1%)
2+	357 (20.5%)
3+	275 (15.7%)
Unknown grade	63 (3.7%)
Negative	476 (21%)
Not recorded	43 (1.9%)
<hr/>	
Culture at diagnosis	
Positive	1,371 (60.5%)
Negative	178 (7.8%)
Non-Tuberculosis	5 (0.2%)
Mycobacterium	
Contaminated	19 (0.8%)
Not recorded	694 (30.6%)

\* involved both pulmonary and extra pulmonary TB

**Table 2:** Frequency of first and second-line drug resistance of MDR-TB in HCMC, 2011-2015

Drug resistance	n/ total tested (%)
Patients with DST result*	491
First line drugs	
Pyrazinamide	210/382 (55.0%)
Ethambutol	298/473 (63.0%)
Streptomycin	439/456 (96.3%)
Second-line drugs	
Fluoroquinolones†	48/378 (12.7%)
Any injectable agents‡	31/384 (8.1%)
All injectable agents	9/115 (7.8%)
Cycloserine	2/240 (0.8%)
Ethionamide/Prothionamide	21/223 (9.4%)

\* A total of 503 DST of 491 patients were retrievable

†fluoroquinolones include moxifloxacin, levofloxacin, ofloxacin

‡ injectable agents include kanamycin, amikacin and capreomycin

**Table 3:** Treatment outcomes of 2,241 MDR-TB patients in HCMC, 2011-2015

Treatment outcome	2011 n (%)	2012 n (%)	2013 n (%)	2014 n (%)	2015 n (%)	Total n (%)
Total (n)	405	365	438	476	577	2,241
Cured	246 (60.7%)	190 (52.1%)	225 (51.4%)	289 (60.7%)	297 (53.3%)	1,247 (55.6%)
Completed	64 (15.8%)	80 (21.9%)	85 (19.4%)	71 (14.9%)	96 (17.2%)	396 (17.7%)
Died	27 (6.67%)	39 (10.7%)	45 (10.3%)	51 (10.7%)	64 (11.5%)	226 (10.1%)
Failed	19 (4.69%)	20 (5.48%)	23 (5.25%)	22 (4.62%)	29 (5.21%)	113 (5%)
Lost to follow-up	49 (12.1%)	36 (9.86%)	60 (13.7%)	43 (9.03%)	71 (12.7%)	259 (11.6%)

Of 259 lost to follow-up patients, median treatment duration was 200 days (IQR: 60-340) with 56% occurring during intensive phase, 17.3% had HIV co-infection, 32% had positive AFB smear and 35.9% had culture positive prior the time of lost to follow-up.